

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Investigating the effectiveness of amitriptyline in preventing headache and sleep disorders in patients with mild brainstorming

Protocol summary

Study aim

Prevention of headache and sleep disorders in patients with traumatic brain injury

Design

This study is a double-blind randomized clinical trial with a control group and parallel groups. Phase 2 was performed on 110 patients and rand function of Excel software was used for randomization.

Settings and conduct

This study is a double-blind randomized clinical trial with patient and researcher blinding, which will be conducted at Al-Zahra Medical Center, Isfahan University of Medical Sciences. The studied population will be patients with mild brain trauma who will be treated with medication to reduce headache and insomnia disorders. In the intervention group, amitriptyline was started with a dose of 10 mg and continued up to 50 mg, and according to the patient's tolerance, it was increased to 25 to 50 mg orally within two weeks, and placebo was prescribed for the control group.

Participants/Inclusion and exclusion criteria

Inclusion in the study: Patient consent to enter the study, patients with a mild concussion with a consciousness quotient between 13-15 Exclusion criteria: patients with a history of any brain disorders, bipolar patients with a family history, patients with long QT and a history of arrhythmia, patients with a history of seizures, a history of headaches and mood disorders

Intervention groups

In the intervention group: Amitriptyline starts at 10 mg and continues to 50 mg and increases to 25 to 50 mg orally within two weeks. In the control group: Plainbo is prescribed (there is no approved treatment for the disease and does not use any specific drug.

Main outcome variables

Headache and sleep disorders

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230627058603N1**

Registration date: **2024-01-03, 1402/10/13**

Registration timing: **retrospective**

Last update: **2024-01-03, 1402/10/13**

Update count: **0**

Registration date

2024-01-03, 1402/10/13

Registrant information

Name

Mehdi Shafiei

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3670 0666

Email address

neurosurgery_resident@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-08-01, 1402/05/10

Expected recruitment end date

2023-09-01, 1402/06/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigating the effectiveness of amitriptyline in preventing headache and sleep disorders in patients with mild brainstorming

Public title

Amitriptyline headache and sleep disorders in patients with mild stroke

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Patient satisfaction to enter the study Patients with mild strokes with a consciousness coefficient of between 13-15

Exclusion criteria:

Patients with moderate and high brain trauma Patients with a history of any brain disorders Bipolar and family history Patients with long QT and arrhythmia history Seizure A history of headaches and mood disorders Incidence of any drug complications

Age

No age limit

Gender

Both

Phase

1-2

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **110**

Randomization (investigator's opinion)

Randomized

Randomization description

Easy sampling methods from those who are eligible to enter the study are randomly divided into two groups of cases and control. In this study, the segmentation of individuals is performed as a quadruple block. In this method A reflects the person who receives the intervention and B represents the person in the control group. Considering the four -block block, we give the AABB Code 0, to the ABAB Code 1, to ABBA Code 2, to BAAB Code 3, to BBAA Code 4 and BABA Code 5 to 9. Then, using the random numbers table, select the starting point randomly and then consider the numbers in a row or column. Considering the order of the table numbers, we replace each number we have hit. Finally, 110 people will be divided into two groups.

Blinding (investigator's opinion)

Double blinded

Blinding description

The researcher does not know which patient received which medicine. In this study, the placebo is just like the original drug and the patient is unaware of which drug he is taking.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Esfahan University of Medical Sciences

Street address

Hazar Jarib Street, Azadi Square

City

Esfahan

Province

Isfahan

Postal code

8174673461

Approval date

2022-04-23, 1401/02/03

Ethics committee reference number

IR.MUI.MED.REC.1401.028

Health conditions studied**1****Description of health condition studied**

Mild brain trauma

ICD-10 code

S06.2

ICD-10 code description

Diffuse traumatic brain injury

Primary outcomes**1****Description**

Headache

Timepoint

6 months after intervention

Method of measurement

HDI Standard Headache Questionnaire

2**Description**

sleep disorders

Timepoint

6 months after intervention

Method of measurement

Pittsburgh's sleep quality questionnaire

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Amitriptyline from Daropakhsh pharmaceutical company started with a dose of 10 mg and continued up to 50 mg, and according to the patient's tolerance, it was increased to 25 to 50 mg orally within two weeks. Medication lasts for three months

Category

Prevention

2

Description

Control group: Plainboast is prescribed. Medication takes over three months. The manufacturer of placebo is Abidi Pharmaceuticals.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-zahra Hospital

Full name of responsible person

Mehdi Shafiei

Street address

Al-Zahra Hospital, Safa Street

City

Esfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 913 310 1971

Email

Mehdishafiei82@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Gholamreza Asgari

Street address

Hazar Jarib Street, Azadi Square

City

Esfahan

Province

Isfahan

Postal code

81746-73461

Phone

+98 31 3668 0048

Email

mui@mui.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

1

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Mehdi Shafiei

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Neurosurgery

Street address

Hazar Jarib Street, Azadi Square

City

Esfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 0048

Email

mui@mui.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Mehdi Shafiei

Position

Assistant Professor

Latest degree

Specialist

Other areas of specialty/work

Neurosurgery
Street address
Hazar Jarib Street, Azadi Square
City
Esfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3668 0048
Email
mui@mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Mehdi Shafiei
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
Hazar Jarib Street, Azadi Square

City
Esfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3668 0048
Email
mui@mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Not applicable

Analytic Code

Not applicable

Data Dictionary

Not applicable